Home/Pipeline/Glassia® (IV AAT)

Glassia® (IV AAT)

Alpha-1 Antitrypsin Deficiency (AATD)

ApprovedCommercial

Key Facts

Indication

Alpha-1 Antitrypsin Deficiency (AATD)

Phase

Approved

Status

Commercial

Company

Kamada

About Kamada

Kamada is a vertically integrated biopharmaceutical company with a dual focus on commercial plasma-derived products and a pipeline of innovative therapeutics. Its flagship product, Glassia®, is an FDA-approved intravenous treatment for alpha-1 antitrypsin deficiency. The company leverages its manufacturing expertise to advance a pipeline of inhaled and plasma-derived therapies, while also engaging in strategic partnerships and contract development and manufacturing (CDMO) services.

View full company profile

Therapeutic Areas

Rare Diseases Pulmonary Hematology Infectious Diseases

Other Alpha-1 Antitrypsin Deficiency (AATD) Drugs

Drug	Company	Phase	Status
BEAM-302	Beam Therapeutics	Preclinical	IND-enabling
WVE-006	WaVe Life Sciences	Phase 1/2	Active - INHALE trial; Accelerating regulatory engagement
INBRX-101	Inhibrx Biosciences	Phase 2	Active
Inhaled AAT (KMA-001)	Kamada	Phase 3	Active
GalNAc Program (SERPINA1 target)	Korro Bio	Discovery	Active
Unnamed AATD Program	AlveoGene	Pre-clinical	Lead Program